01/22/2026
A new study, published in Annals of Internal Medicine and led by Joe Eron, MD, Director of the CFAR Clinical Core, found that a new once-weekly oral HIV treatment regimen of islatravir plus lenacapavir (ISL + LEN) achieved virologic suppression through 48 weeks. These findings suggest that a once-weekly oral HIV treatment regimen could help reduce barriers associated with adhering to a daily pill for people living with HIV. Dr. Joe Eron discussed, “People living with HIV deserve options that work not only medically, but practically. Daily pills are effective, but they’re not the right fit for everyone. Seeing such strong suppression with a once‑weekly regimen is incredibly encouraging. It suggests we may be able to offer patients a simpler approach that still delivers the control they need.”
Read more here: https://www.med.unc.edu/cfar/2026/01/new-once-weekly-hiv-oral-regimen-shows-strong-results-after-48-weeks/